SCHEMBL1736660

SCHEMBL1736660

O=C(Cc1ccccc1)NCP(=O)(O)Oc1cccc(C(=O)O)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR4A2 P43354 3/20 0.49
KMT2A Q03164 4/20 0.47
MEN1 O00255 1/20 0.47
NR1H4 Q96RI1 1/20 0.46
SMPD1 P17405 1/20 0.45
HTT P42858 1/20 0.45
AKR1C3 P42330 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
HDAC3 O15379 1/20 0.43
HDAC4 P56524 1/20 0.43
HDAC1 Q13547 1/20 0.43
HDAC7 Q8WUI4 1/20 0.43
HDAC2 Q92769 1/20 0.43
HDAC10 Q969S8 1/20 0.43
HDAC11 Q96DB2 1/20 0.43
HDAC8 Q9BY41 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43
HDAC9 Q9UKV0 1/20 0.43
HDAC5 Q9UQL6 1/20 0.43
ALDH1A1 P00352 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1736661 0.89 NR4A2 (0.50) NR4A2KMT2AMEN1NR1H4SMPD1
SCHEMBL3661539 0.77 ALDH1A1 (0.55) KMT2AMEN1SMN1; SMN2HDAC3HDAC4
SCHEMBL29375550 0.76 NR4A2 (0.52) NR4A2KMT2AMEN1NR1H4AKR1C3
SCHEMBL3661541 0.74 PLAU (0.48) NR4A2KMT2AMEN1SMN1; SMN2HDAC3
SCHEMBL28845536 0.72 AKR1C3 (0.61) NR4A2KMT2ANR1H4AKR1C3HDAC8
SCHEMBL16011563 0.72 NR4A2 (0.66) NR4A2KMT2AMEN1NR1H4SMPD1
SCHEMBL9178371 0.72 AKR1C3 (0.59) NR4A2KMT2ANR1H4AKR1C3MRGPRX4
SCHEMBL17400975 0.72 NR4A2 (0.61) NR4A2KMT2AMEN1NR1H4SMPD1
SCHEMBL18486571 0.70 AKR1C3 (0.61) NR4A2KMT2ANR1H4AKR1C3MRGPRX4
SCHEMBL14075341 0.70 ALDH1A1 (0.65) NR4A2KMT2AMEN1NR1H4AKR1C3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150258202-A1 ANTHOCYANIDIN COMPLEX FOR THE TREATMENT OF MULTIPLE MYELOMA SAPIOTEC GMBH (DE) 2015-09-17 US disclosed
US-8658686-B2 Pyrazole compounds having therapeutic effect on multiple myeloma NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2014-02-25 US disclosed
US-20130253204-A1 PYRAZOLE COMPOUNDS HAVING THERAPEUTIC EFFECT ON MULTIPLE MYELOMA NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2013-09-26 US disclosed
EP-2139482-B1 TREATMENT FOR MULTIPLE MYELOMA ARES TRADING SA (CH) 2011-11-16 EP disclosed
WO-2011133654-A1 ADJUSTABLE WALL SUPPORT SYSTEM AND METHOD MODERNFOLD, INC. (US) 2011-10-27 WO disclosed
US-20100069316-A1 TREATMENT FOR MULTIPLE MYELOMA ARES TRADING S.A. 2010-03-18 US disclosed
EP-1635806-B1 METHOD FOR TREATING ALCOHOLIC HEPATITIS UNIV PITTSBURGH (US) 2008-05-28 EP disclosed
US-7238489-B2 Identification of sortase gene THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2007-07-03 US disclosed
US-20060223887-A1 Method for treating acute pancreatitis UNIVERSITY OF PITTSBURGH- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 2006-10-05 US disclosed
US-7101692-B2 Identification of sortase gene THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2006-09-05 US disclosed
US-6773706-B2 Identification of sortase gene THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2004-08-10 US disclosed
EP-1416955-A2 IDENTIFICATION OF SORTASE GENE The Regents of the University of California (US) 2004-05-12 EP disclosed
WO-2003020885-A9 IDENTIFICATION OF SORTASE GENE UNIV CALIFORNIA (US) 2004-04-01 WO disclosed
US-20030153020-A1 Identification of sortase gene NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2003-08-14 US disclosed
US-6565895-B2 Side-effect reduction of anti-cancer therapy GELTEX PHARMACEUTICALS, INC. 2003-05-20 US disclosed
WO-2003020885-A2 IDENTIFICATION OF SORTASE GENE THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2003-03-13 WO disclosed
US-20030022178-A1 Identification of sortase gene NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2003-01-30 US disclosed
EP-1233780-A1 IDENTIFICATION OF SORTASE GENE The Regents of the University of California (US) 2002-08-28 EP disclosed
US-20020081340-A1 Bismuth compounds for the treatment and prevention of mucositis GELTEX PHARMACEUTICALS, INC. 2002-06-27 US disclosed
WO-2000062804-A2 IDENTIFICATION OF SORTASE GENE THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2000-10-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060223887-A1 Method for treating acute pancreatitis PNLIP, LIPA, AMY2A NR4A2 4116/4885KMT2A 2730/4885MEN1 4476/4885
US-20100069316-A1 TREATMENT FOR MULTIPLE MYELOMA MCL1, BCL6, BCL6B NR4A2 3578/4885KMT2A 931/4885MEN1 64/4885
US-20150258202-A1 ANTHOCYANIDIN COMPLEX FOR THE TREATMENT OF MULTIPLE MYELOMA SDCBP, BCL9, BCL9L NR4A2 2062/4885KMT2A 2720/4885MEN1 706/4885
US-20130253204-A1 PYRAZOLE COMPOUNDS HAVING THERAPEUTIC EFFECT ON MULTIPLE MYELOMA MCL1, BCL6, RTN3 NR4A2 1997/4885KMT2A 1201/4885MEN1 377/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.